Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

>> Preview...
You are here: Home » Industry Insights

Industry Insights

Print

Science and business issues impacting the China biotech industry...

Recent Articles

  VC Investment, M&A and Cross-border Partnerships Boom in China Life Science
Jan 21, 2013
China has declared it wants to be the world’s leader in drug innovation, and its life science sector made remarkable progress toward becoming a global leader in 2012. “In the world of China life science, VC investment, M&A transactions, partnering activity, especially cross-border deals – all of these metrics were up substantially last year,” said Greg B. Scott, CEO and Founder of ChinaBio® LLC, a consulting and advisory firm based in Shanghai. We have the details...

Share this with colleagues:  

  China Leads Emerging Nations in Pharma M&A
Dec 12, 2012
Drug companies are increasing their M&A spending in emerging markets, and China is garnering the lion’s share of activity, according to data from Thomson Reuters. All together, including capital from both overseas and domestic drug manufacturers, M&A in emerging countries has totaled $20 billion this year. That’s a jump of 67% over last year. China deals were responsible for one-third of the total: $6.8 billion. More details....

Share this with colleagues:  

  China Announces Another Round of Drug Price Cuts
Sep 20, 2012
In a widely expected move, China ordered an average 17% reduction in the maximum retail prices of 95 cancer, immunology and blood-related drugs, many of them produced by foreign drugmakers. Unlike earlier rounds of price cuts, this one concentrated on drugs with high daily costs. Especially hard hit were drugs with “separated pricing” – the drugs available from a foreign manufacturer at a higher price than their China generic equivalents. At the same time, China’s NDRC reiterated support for prices that are high enough to encourage innovative drug research. More details....

Share this with colleagues:  

  Barclays Upgrades Outlook on Companies in China Healthcare Sector
Aug 3, 2012
Barclays Bank has raised its rating for companies in the China healthcare sector, moving to Positive. Six months ago, Barclays gave the sector a Negative rating. In fact, Jason Mann, MD, PhD, who is responsible for Barclays’ coverage of China‘s healthcare companies, titled his latest report “Clearer Skies Ahead." Dr. Mann based his improving outlook in part on a survey, conducted by ChinaBio®, showing that industry insiders have grown more optimistic about the future for their sector over the last six months. More details....

Share this with colleagues:  

  India Unhappy about China’s Dominance in Antibiotic APIs
Jun 5, 2012
India wants its generic drug industry to be self-sufficient. However, the country remains dependent upon China’s API and drug intermediate companies, especially in the areas of penicillin-type antibiotics. Although India is home to a vibrant group of companies that produce finished generic drugs, these companies source many of their raw materials from China—about two-thirds of the total. More details....

Share this with colleagues:  

  China’s State Council Reiterates Support for Biotechnology
May 30, 2012
The State Council of China said it will increase support for seven high-technology industries – including biotechnology – as a way to stimulate growth in its economy. After all, growth is at a three-year low. In 2012’s first quarter China’s gross domestic product increased at only an 8.1% rate, anemic by China’s standards. The slowdown has caused speculation the country will announce a stimulus to rev up the economy. But a straight-out stimulus gives rise to criticism that China is creating artificial growth in an economy that has lost momentum. To avoid that, China may concentrate its investment in its seven favorite industries. Then the stimulus becomes a way of achieving its long-term goals while it also gives a short-term boost to the economy. More details....

Share this with colleagues:  

  Roche Cuts the Price of Cancer Drugs in India – Under Pressure?
Mar 28, 2012
Last week, Roche said it would “significantly” reduce the price the company charges in India for two expensive biotech cancer drugs – Herceptin and MabThera (known as Rituxin in the US). The move came two weeks after India stripped Bayer of its exclusive license to market the cancer treatment Nexavar in India. As part of the ruling, India allowed a local company to produce Nexavar at a price of $172 per month, a 97% reduction from the $5,500 that Bayer charged. To most people, the two stories seem related, even though Roche would not say the implicit pressure from Indian authorities was responsible for its price reductions. More details....

Stock Symbols:  (VX: ROG) (Xetra: BAY)

Share this with colleagues:  

  ChinaBio® White Paper – China Life Science: From Local to Global
Mar 20, 2012
When China celebrated its New Year during January, it entered the Year of the Dragon, a symbol of wealth and power. The dragon also signifies transformation and rapid change. While change has been building in China’s life science industry for years, a transformation coalesced in 2011. Last year, China life science transformed itself from an industry with primarily local, inward-looking domestic companies to a sector that has global impact. ChinaBio® has just published a White Paper, available for free on its website (www.chinabiotoday.com/downloads/20120313), detailing the growth of global activity in China’s life science sector during 2011. More details....
  China’s Pressure on Drug Prices May Hurt Outlook for Pharma
Mar 15, 2012
China’s aggressive cost-cutting of drug prices, especially generics, has put a cloud over the country’s pharmaceutical industry. A number of domestic companies, announcing their 2011 full-year results, have blamed the government’s control of prices for shortfalls in revenues and profits. According to Jason Mann, MD, PhD, Head of Pharma/Healthcare for Barclays Capital in Hong Kong, China can’t expect much change in the direction of policy before the ruling Communist Party appoints a new generation of leaders later this year. More details....

Share this with colleagues:  

  WHO Certification a Shot-in-the-Arm for China Vaccine Makers
Dec 1, 2011
On March 1, 2011, the World Health Organization certified that the SFDA’s standards meet international criteria for vaccine supervision. Other regulatory hurdles remain, but the WHO imprimatur means China vaccine makers will eventually be able to supply vaccines to resource-poor nations through UN-related agencies, a huge market. Over time, the WHO action could transform China’s vaccine industry. More details....

Share this with colleagues:  
 
more articles >>
Login

  

    
   
  Subscribe 
Forgot password?
>> Login help...
ChinaBio® Events

ChinaBio® Partnering Forum 2013
  May 29-30, 2013
Beijing, China

>>More events...
Partner Events

China Medical Affairs Summit
  June 18-19, 2013
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners